Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. SPY
2. USO
3. IONQ
4. IONS
5. ROIV
6. AAPL
7. HOOD
8. QCOM
9. ACN
10. AZN

Go back to Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas
(NYSE: PRTO) Delayed: 28.03 -0.15 (0.53%)
Previous Close $28.18    52 Week High $16.48 
Open $28.10    52 Week Low $4.90 
Day High $28.11    P/E N/A 
Day Low $28.03    EPS $0.00 
Volume 498